Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/29372
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Rodrigues, Manuel Lima | - |
dc.contributor.author | Lamas, Nuno Jorge | - |
dc.contributor.author | Fernandes, Ana Valle | - |
dc.contributor.author | Cruz, Andrea | - |
dc.contributor.author | Vieira, Artur Jorge Gomes | - |
dc.contributor.author | Oliveira, Pedro | - |
dc.contributor.author | Pedrosa, Jorge | - |
dc.contributor.author | Castro, António G. | - |
dc.contributor.author | Reis, R. M. | - |
dc.contributor.author | Baltazar, Fátima | - |
dc.contributor.author | Almeida, Armando | - |
dc.date.accessioned | 2014-06-18T14:18:47Z | - |
dc.date.available | 2014-06-18T14:18:47Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1023-3830 | por |
dc.identifier.uri | https://hdl.handle.net/1822/29372 | - |
dc.description | The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment. | por |
dc.description.abstract | OBJECTIVE: A randomised experimental study was used to evaluate the therapeutic effect of a selective cyclooxygenase-2 (COX-2) inhibitor in neurogenic laryngitis. MATERIALS AND METHODS: Male Wistar Han rats were subjected to the nasogastric intubation model (NGI) of laryngitis for 1 and 2 weeks. The NGI animals were divided into three groups: (1) treated with COX-2 inhibitor Etoricoxib, (2) vehicle and (3) non-intubated animals. A fourth group of animals was submitted to NGI only. Laryngeal sections were immunostained for substance P (SP) and calcitonin gene-related peptide (CGRP) fibre-immunoreactivity (IR) and quantification of COX-2 positive cells through stereological analysis. The expression of COX-2, interleukins IL-1beta, IL-6, IL-10 and tumour necrosis factor-alpha (TNF-alpha) was determined by quantitative real time QRT-PCR. TREATMENT: Etoricoxib (6 mg/kg/day) was prepared in 0.9% sterile saline with 5% glucose (vehicle) and administered daily during 1 or 2 weeks. RESULTS: Treatment for 1 week with Etoricoxib attenuated the CGRP-IR fibre depletion, the COX-2-IR increased cell number and the TNF-alpha and COX-2 mRNA increased levels induced by NGI. Two weeks of treatment had no beneficial effect. CONCLUSIONS: Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future. | por |
dc.description.sponsorship | This study was supported by Fundacao Calouste Gulbenkian Project No 74551 and Fundacao Grunenthal (Portugal). | por |
dc.language.iso | eng | por |
dc.publisher | Springer | por |
dc.rights | openAccess | por |
dc.subject | Neurogenic laryngitis | por |
dc.subject | Nasogastric intubation (NGI) model | por |
dc.subject | Quantitative real-time QRT-PCR | por |
dc.subject | Selective COX-2 inhibitor | por |
dc.subject | Tumor necrosis factor-a (TNF-a) | por |
dc.title | The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | http://link.springer.com/article/10.1007%2Fs00011-010-0185-5 | por |
sdum.publicationstatus | published | por |
oaire.citationStartPage | 1 | por |
oaire.citationEndPage | 11 | por |
oaire.citationIssue | 9 | por |
oaire.citationTitle | Inflammation Research | por |
oaire.citationVolume | 59 | por |
dc.date.updated | 2014-06-13T08:49:03Z | - |
dc.identifier.doi | 10.1007/s00011-010-0185-5 | por |
dc.identifier.pmid | 20349107 | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Inflammation Research | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
lima-rodrigues m_ inflamm res 2010 posp.pdf | 1,81 MB | Adobe PDF | Ver/Abrir |